Compare SSB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSB | TGTX |
|---|---|---|
| Founded | 1933 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.5B |
| IPO Year | 2008 | 2008 |
| Metric | SSB | TGTX |
|---|---|---|
| Price | $102.54 | $54.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $118.64 | $69.71 |
| AVG Volume (30 Days) | 610.1K | ★ 1.5M |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | 12.91 | ★ 1746.67 |
| EPS | ★ 4.64 | 0.17 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $1.82 | $55.81 |
| Revenue Next Year | $6.61 | $37.36 |
| P/E Ratio | ★ $21.86 | $313.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.48 | $26.76 |
| 52 Week High | $112.20 | $59.30 |
| Indicator | SSB | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 44.79 |
| Support Level | $100.33 | $51.68 |
| Resistance Level | $102.17 | $58.26 |
| Average True Range (ATR) | 1.80 | 1.89 |
| MACD | 0.30 | -0.13 |
| Stochastic Oscillator | 63.98 | 34.73 |
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time, and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.